In conclusion, in this in vivo model of flow-associated PAH we showed that EPO treatment restored the number of circulating EPCs to control level, improved pulmonary vascular remodeling, and showed important interplay with HO activity. This evidence concerns the gene EPO and pulmonary arterial hypertension.